These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27819149

  • 1. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N, Colivicchi F.
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE, Merino JL, Barrios V.
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 10. Edoxaban: A direct oral anticoagulant.
    Poulakos M, Walker JN, Baig U, David T.
    Am J Health Syst Pharm; 2017 Feb 01; 74(3):117-129. PubMed ID: 28122753
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Edoxaban in patients with atrial fibrillation.
    Eisen A, Ruff CT.
    Ther Adv Cardiovasc Dis; 2017 Mar 01; 11(3):81-90. PubMed ID: 26680560
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
    Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EM, Giugliano RP.
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul 01; 6(3):167-175. PubMed ID: 31687762
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
    Hawkins NM, Jhund PS, Pozzi A, O'Meara E, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, Virani S, McMurray JJ.
    Eur J Heart Fail; 2016 Sep 01; 18(9):1162-71. PubMed ID: 27594177
    [Abstract] [Full Text] [Related]

  • 20. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P, ETNA-AF-Europe investigators.
    BMC Cardiovasc Disord; 2019 Jul 12; 19(1):165. PubMed ID: 31299906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.